Core Viewpoint - scPharmaceuticals Inc. is set to discuss its financial results for Q4 and full year 2024 during a conference call on March 19, 2025, highlighting its commitment to cardiorenal healthcare innovations [1] Company Overview - scPharmaceuticals is dedicated to revolutionizing cardiorenal healthcare through patient-centric innovations, focusing on advancing care with integrated treatments that address unmet patient needs [3][4] - The company aims to be a leading advocate for patient-centric cardiorenal care, promoting global health improvements through specialized, multidisciplinary approaches [4] Conference Call Details - The conference call will take place at 4:30 p.m. ET on March 19, 2025, and will include a business update alongside the financial results discussion [1] - Registration for the conference call can be completed via a direct link, and the live webcast will be accessible on the company's website [2]

Core Viewpoint - The FDA has approved scPharmaceuticals' supplemental New Drug Application (sNDA) for FUROSCIX, expanding its indication to treat edema in adult patients with chronic kidney disease (CKD), including nephrotic syndrome, with availability expected in April 2025 [1][2]. Company Overview - scPharmaceuticals is focused on revolutionizing cardiorenal healthcare through patient-centric innovations and aims to address unmet needs in the cardiorenal patient population [1][11]. - The company has taken strategic steps to ensure a successful launch of FUROSCIX, including engaging key opinion leaders, conducting comprehensive market research, and preparing for commercial readiness [2]. Product Information - FUROSCIX® (furosemide injection) is indicated for the treatment of edema in adult patients with chronic heart failure or CKD, including nephrotic syndrome [3]. - The product is expected to provide clinicians with an additional tool for managing fluid overload in CKD patients, potentially allowing them to keep patients at home while restoring and maintaining euvolemia [2]. Safety Information - FUROSCIX is contraindicated in patients with anuria and those with a history of hypersensitivity to furosemide or its components [4]. - Common adverse reactions include site and skin reactions such as erythema, bruising, edema, and injection site pain [10].

Company Overview - ScPharmaceuticals, Inc. (SCPH) is expected to report a quarterly loss of $0.40 per share, reflecting a year-over-year decline of 14.3% [3] - The company's revenues are projected to be $12.04 million, which represents a significant increase of 97.4% compared to the same quarter last year [3] Earnings Expectations - The consensus EPS estimate has remained unchanged over the last 30 days, indicating stability in analyst expectations [4] - The Most Accurate Estimate for ScPharmaceuticals is higher than the Zacks Consensus Estimate, resulting in a positive Earnings ESP of +2.50%, suggesting a bullish outlook from analysts [10] Historical Performance - In the last reported quarter, ScPharmaceuticals was expected to post a loss of $0.30 per share but actually reported a loss of $0.37, resulting in a surprise of -23.33% [12] - Over the past four quarters, the company has beaten consensus EPS estimates two times [13] Industry Context - Another company in the same industry, BioXcel Therapeutics, Inc. (BTAI), is expected to report a loss of $4.36 per share, indicating a year-over-year change of +64.1%, with revenues expected to decline by 60.5% to $0.15 million [17] - BioXcel's consensus EPS estimate has remained unchanged, but a lower Most Accurate Estimate has led to a negative Earnings ESP of -15.50%, complicating predictions for an earnings beat [18]

Core Viewpoint - scPharmaceuticals Inc. is focused on revolutionizing cardiorenal healthcare through patient-centric innovations and will present at upcoming investor conferences [1][2][3] Company Overview - scPharmaceuticals is dedicated to advancing cardiorenal care with innovative, integrated treatments that address unmet patient needs [2][3] - The company aims to be a leading advocate for patient-centric cardiorenal care, promoting global health improvements through specialized, multidisciplinary approaches [3] Upcoming Events - John Tucker, President and CEO, will present at the Annual TD Cowen Healthcare Conference on March 5 at 11:10 AM ET [4] - The company will also have a corporate presentation at the Leerink Partners 2025 Global Healthcare Conference on March 11 at 2:20 PM ET [4]

Company Overview - scPharmaceuticals Inc. is a pharmaceutical company focused on revolutionizing cardiorenal healthcare through patient-centric innovations [1][3] - The company's mission is to advance cardiorenal care with integrated treatments that address unmet patient needs [3][4] Upcoming Event - John Tucker, President & CEO of scPharmaceuticals, will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 12 at 2:40 PM ET [1] - A webcast of the presentation will be available on the company's website under the "News & Events" section [2] Strategic Goals - The company aims to be the foremost advocate for patient-centric cardiorenal care, driving global health improvements through specialized, multidisciplinary approaches [4] - scPharmaceuticals is expanding its reach by offering integrated therapies and products that address diverse healthcare needs [4]

Revenue Performance - Preliminary unaudited fourth quarter FUROSCIX net revenue is expected to be in the range of $12.0 million to $12.3 million, representing a 22% increase from the third quarter of 2024 at the mid-point of the range [8]. - Preliminary unaudited full year 2024 FUROSCIX net revenue is expected to be in the range of $36.2 million to $36.5 million, representing 167% growth over the full year 2023 at the mid-point of the range [8]. Product Shipment - Approximately 13,300 FUROSCIX doses shipped in the fourth quarter, representing an approximately 23% increase from the 10,800 doses shipped in the third quarter of 2024 [8]. Financial Metrics - The gross-to-net discount is expected to be in the range of 18% to 19%, compared to the gross-to-net discount of 15.7% in the third quarter of 2024 [8]. - Unaudited cash, cash equivalents and short-term investments were approximately $75.7 million as of December 31, 2024, which does not include an approximate increase in accounts receivable of 27% over the balance as of September 30, 2024 [8]. Operational Improvements - A specialty pharmacy was added to improve coverage of expanded geography [8].

Core Insights - scPharmaceuticals Inc. expects preliminary unaudited fourth quarter 2024 net revenue to be approximately $12 million to $12.3 million, indicating a 99% growth over Q4 2023 at the mid-point of the range [1] - The company anticipates full year 2024 net revenue to be around $36.2 million to $36.5 million, compared to $13.6 million for full year 2023, representing a growth of 167% at the mid-point of the range [1][7] - The gross-to-net (GTN) discount for Q4 2024 is expected to be in the range of 18% to 19%, an increase from 15.7% in Q3 2024 [1][7] Financial Performance - Approximately 13,300 FUROSCIX doses were shipped in Q4 2024, reflecting a 23% increase from 10,800 doses shipped in Q3 2024 [7] - As of December 31, 2024, unaudited cash and cash equivalents were approximately $75.7 million, with an approximate 27% increase in accounts receivable over the balance as of September 30, 2024 [7] Strategic Initiatives - The growth in FUROSCIX net revenue is driven by ongoing expansion efforts, including collaborations with top Integrated Delivery Networks and hospital systems, as well as the initial impact of an expanded field sales force [2] - The company anticipates further growth in Class IV heart failure patients and plans to submit a supplemental New Drug Application (sNDA) for its Autoinjector product candidate mid-year, which is expected to accelerate future growth [2]

Financial Data and Key Metrics Changes - The company generated net revenue of $10 million in Q3 2024, representing a 24% increase from Q2 2024 [8] - The gross net discount for FUROSCIX was approximately 15.7%, exceeding the guided range of 10% to 15% [9] - The net loss for Q3 2024 was $35.1 million, compared to $15.6 million in Q3 2023, primarily due to one-time charges [27][28] Business Line Data and Key Metrics Changes - Approximately 3,100 unique healthcare providers prescribed FUROSCIX, a 13% increase compared to Q2 2024 [18] - The company filled approximately 10,800 doses of FUROSCIX, a 16% increase from the previous quarter, with the average number of doses per prescription rising to 6.8 [19] - The acceptance of the sNDA filing by the FDA for expanding FUROSCIX's indication to include CKD patients was a significant achievement [12] Market Data and Key Metrics Changes - The company anticipates that the GTN discount will increase to 35% by the end of 2025 due to the Medicare Part D redesign [9] - The company ended Q3 2024 with $91.5 million in cash and cash equivalents, up from $76 million at the end of 2023 [28] Company Strategy and Development Direction - The company is focused on expanding FUROSCIX's indications to cover all heart failure patients, including Class IV patients, which represent a significant portion of hospitalizations [10] - The company is preparing for a potential launch of FUROSCIX for CKD, with a PDUFA date set for March 6, 2025 [14] - The transformative financing completed in August 2024 added approximately $75 million to the balance sheet, supporting projected cash flow through expected profitability [16] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about growth driven by sales force expansion and indication expansion for FUROSCIX [8] - The management noted that the fourth quarter is expected to be the biggest opportunity of the year due to increased hospital admissions related to fluid overload during the holiday season [34] - Management highlighted the positive reception from nephrologists regarding FUROSCIX, indicating a strong potential for the CKD market [42] Other Important Information - The company is working on a low-volume Autoinjector, which demonstrated promising results in a PK/PD bridging study [15] - The new FUROSCIX direct patient services hub has improved the prescribing process, receiving positive feedback from healthcare providers [20] Q&A Session Summary Question: What do you think the doses per prescription could look like for FUROSCIX and CKD relative to heart failure? - Management indicated that doses for CKD would be similar to Class II and Class III heart failure patients, around 6.0 to 6.5 [31] Question: What do you think the rate of on-body diffuser versus autoinjector could shake out to in the long-term? - Management projected that over 90% of treatments would be in the autoinjector format, with some patients likely to remain on the current system [32] Question: Is there any expected seasonality that we could see in Q4? - Management confirmed that Q4 is expected to have the highest sales due to increased hospital admissions related to fluid overload during the holidays [34] Question: What percentage of prescriptions do you think will be Class IV as you exit the year? - Management noted that Class IV patients currently represent about 10% of prescriptions, with expectations for growth [38] Question: Can you comment on how the initial nephrology detailing is going? - Management reported positive reception from nephrologists, with many expressing interest in prescribing FUROSCIX [42] Question: What led to a slower end to the quarter than expected? - Management attributed the slowdown to coverage gap rebates affecting fill rates, despite continued growth in script writing [45][46] Question: What was the conversion rate in the third quarter? - The fill rate for prescriptions was 53%, an increase from 48% in Q2 [48] Question: How do you see the conversion rate going into next year with the Part D redesign? - Management projected a fill rate of 65% for next year, benefiting from the redesign and increased affordability for patients [55]

ScPharmaceuticals, Inc. (SCPH) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of $0.30. This compares to loss of $0.41 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -23.33%. A quarter ago, it was expected that this company would post a loss of $0.44 per share when it actually produced a loss of $0.44, delivering no surprise.Over the last four quarters, the company has surpasse ...

Generated 3Q 2024 net FUROSCIX® revenue of $10.0 million, up 164% from Q3 2023 Received approval of label expansion to include New York Heart Association (NYHA) Class IV Patients Announced positive pharmacokinetic/pharmacodynamic (PK/PD) data on Autoinjector program Completed $125 million transformative financing in a combination of debt and equity that is anticipated to fund the Company through expected profitability Company to host investor conference call and webcast today, Wednesday, November 13th, at ...